Classification
Leiomyosarcomas are now staged using the 2009 FIGO staging system (previously they were staged like endometrial carcinomas)  at the time of surgery. Stage I: tumor is limited to the uterusIA: ≤5 cm in greatest dimension
IB: >5 cmStage II: tumor extends beyond the uterus, but within the pelvisIIA: involves adnexa of uterus
IIB: involves other pelvic tissuesStage III: tumor infiltrates abdominal tissuesIIIA: 1 site
IIIB: >1 site
IIIC: regional lymph node metastasisStage IVA: invades bladder or rectum
Stage IVB: distant metastasis (including intra-abdominal or inguinal lymph nodes; excluding adnexa, pelvic and abdominal tissues)Endometrial stromal sarcomas and uterine adenosarcomas are classified as above, with the exception of different classifications for Stage I tumors. Stage I: the tumor is limited to the uterusIA: limited to endometrium/endocervix
IB: invades <½ myometrium
IC: invades ≥½ myometriumFinally, malignant mixed Müllerian tumors, a type of carcinosarcoma, are staged similarly to endometrial carcinomas. Stage I: the tumor is limited to the uterusIA: invades <½ myometrium
IB: invades ≥½ myometriumStage II: invades cervical stroma, but no extension beyond the uterus
Stage III: local and/or regional spreadIIIA: invades uterine serosa and/or adnexa
IIIB: vaginal and/or parametrial involvement
IIIC: metastases to pelvic and/or paraaortic lymph nodes
IIIC1: positive pelvic nodes
IIIC2: positive para-aortic lymph nodesStage IVA: invades bladder and/or bowel mucosa
Stage IVB: distant metastases (including intra-abdominal metastases and/or inguinal lymph nodes)

Management
Therapy is based on staging and patient condition and utilizes one or more of the following approaches. Surgery is the mainstay of therapy if feasible involving total abdominal hysterectomy with bilateral salpingo-oophorectomy. Other approaches include radiation therapy, chemotherapy, and hormonal therapy. Prognosis is relatively poor.
High dose of co-amoxiclav (20 mg/kg for amoxicillin and 5 mg/kg for clavulanate) is recommended to prevent treatment failures. Intravenous antibiotics are given for a minimum of 10 to 14 days. The median fever clearance time in melioidosis is 9 days. The treatment duration is in accordance with Darwin melioidosis treatment guidelines where there is low rate of recrudescence and relapse.Meropenem is the preferred antibiotic therapy for neurological melioidosis and those with septic shock admitted into intensive care units. Co-trimoxazole is recommended in addition to ceftazidime for neurological melioidosis, osteomyelitis, septic arthritis, skin and gastrointestinal infection, and deeply seated abscess. For deep-seated infections such as abscesses of internal organs, osteomyelitis, septic arthritis, and neurological melioidosis, the duration of antibiotics given should be longer (up to 4 to 8 weeks). The time taken for the fever to be resolved can be more than 10 days in those with deep-seated infection. According to the 2020 Revised Royal Darwin Hospital Guideline, the dosage for intravenous ceftazidime is 2g 6-hourly in adults (50 mg/kg up to 2g in children less than 15 years old). The dosage for meropenem is 1g 8-hourly in adults (25 mg/kg up to 1g in children). Acquired resistance to ceftazidime, carbapenems, and co-amoxiclav is rare in the intensive phase but resistance to cotrimoxazole during eradication therapy is technically difficult to assess. There are no differences between using cefoperazone/sulbactam or ceftazidime to treat melioidosis as both shows similar death rates and disease progression following treatment. However, data are lacking to recommend cefoperazone/sulbactam usage.